Clozapine response and plasma catecholamines and their metabolites.
The atypical neuroleptic clozapine has an unusual profile of clinical effects and a distinctive spectrum of pharmacological actions. Plasma measures of catecholamines and their metabolites have been used in the past to study the action of typical neuroleptics. We obtained longitudinal assessments of plasma measures of dopamine (pDA), norepinephrine (pNE), and their metabolites, homovanillic acid (pHVA) and 3-methoxy-4-hydroxyphenylglycol (pMHPG), in eight treatment-resistant or treatment-intolerant schizophrenic patients who were treated with clozapine for 12 weeks following a prolonged drug-washout period. Our findings from the study of these eight patients suggest the following: Plasma levels of HVA and possibly NE derived from the neuroleptic-free baseline period may predict response to clozapine; plasma levels of HVA and MHPG decrease during the initial weeks of treatment in responders but not in nonresponders; and plasma levels of DA and NE increase in both responders and nonresponders to clozapine.
Green
A I
AI
Commonwealth Research Center, Massachusetts Mental Health Center.
Alam
M Y
MY
Sobieraj
J T
JT
Pappalardo
K M
KM
Waternaux
C
C
Salzman
C
C
Schatzberg
A F
AF
Schildkraut
J J
JJ
D000328:Adult; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D002395:Catecholamines / Q000097:blood* / Q000378:metabolism; D003024:Clozapine / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006719:Homovanillic Acid / Q000032:analysis / Q000097:blood / Q000378:metabolism; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000032:analysis / Q000097:blood / Q000378:metabolism; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism
D002395:Catecholamines; D008734:Methoxyhydroxyphenylglycol; D003024:Clozapine; D006719:Homovanillic Acid